Can a more intense radiation schedule outperform Chemo-Radiation for head and neck cancer?
NCT ID NCT00162708
First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time
Summary
This trial tests two aggressive radiation therapy schedules for people with advanced head and neck cancer that cannot be removed with surgery. One approach uses a very intense radiation schedule combined with chemotherapy, while the other uses a very accelerated radiation schedule alone. The goal is to see which strategy better prevents the cancer from growing or spreading, and to compare side effects and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Radiotherapy (very accelerated or very intense) with or without chemotherapy (cisplatin and 5-fluorouracil)
- What this could lead to
- If successful, this could identify a more effective radiation schedule, with or without chemo, to improve control of advanced head and neck cancers.
- What could go wrong
- This is a phase 2/3 trial, so results are not guaranteed. The intense treatments may increase side effects, and the study is limited to a specific group of patients with inoperable tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
120 people
- Start date
-
Jul 1996
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * palpable N2b-c or N3 (UICC 1997) squamous cell carcinoma of the head and neck (oropharynx, oral cavity, hypopharynx or larynx) * primary tumor and / or nodal extension strictly inoperable due to the extension of the disease * performance status of 0 to 2 (WHO scoring system) * renal/liver/cardiac functions and blood counts compatible with the use of CDDP and 5-FU * signed inform consent Exclusion Criteria: * distant metastasis * previous history of cancer * previous radiotherapy or chemotherapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Head and neck squamous cell carcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Alexis Vautrin
Nancy, France
-
Centre Jean Perrin
Clermont-Ferrand, France
-
Institut Gustave Roussy
Villejuif, 94800, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): an open label, single-arm, phase II clinical trial
- Can a new drug shrink advanced solid tumors?
- Can steroid shots shield salivary glands from radiation damage?
- Can a new pill boost Immunotherapy's power against advanced tumors?
- Can a glowing light reveal hidden mouth lesions?
- Can heat make radiation more effective against head and neck cancer?